Top Tweets for #RemeGen
APAC Biopharma (Jan 12–16): #RemeGen/@abbvie $5.6B; #SciNeuro/@Novartis $1.5B; @SinoBiopharm buys #Hygieia RMB1.2B; @NxeraPharma #Vamorolone APAC $205M; #WuXiXDC→#BioDlink; @PharmaEssentia #Ropeg ET @FDA PDUFA 2026-08-30; TW #Pharmosa/@Liquidia_Corp L606 Ph3; #HandaBiotech #PHYRAGO; #FormosaPharma #APP13007→ #SamilPharmaceutical; #CMUH αDAT-EV; #MOHW/#NHIA +NT$370M; #TaiwanCDC #PCV20 2.45M.
#GeneOnline
💊@AbbVie_ES y #RemeGen anuncian un acuerdo exclusivo de licencia para desarrollar un anticuerpo biespecífico para tumores sólidos avanzados
https://t.co/MuGk0CoazD
2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China #RemeGen https://t.co/80ix2FV3lq
🇨🇳 #RemeGen announced that the supplementary application for tis BLyS/APRIL fusion protein telitacicept, for the treatment of Sjogren's syndrome, accepted CDE of China's #NMPA.
Today, RemeGen's stock price rose 11.9% on the Shanghai Stock Exchange and 7.9% on the Hong Kong Stock Exchange.
Currently, telitacicept's Sjogren's syndrome indication has received Fast Track designation from the FDA and has been approved to conduct Ph3 clinical trials in the US.
The drug has already been approved for marketing in China for three indications: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG).
🇨🇳#RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries https://t.co/6Ui5ebjNZl
#licensing region: Greater China (including Mainland China, Hong Kong, Macau, and Taiwan) as well as in South Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia, and Malaysia
RC28-E is a VEGF/FGF dual-target fusion protein drug for ocular neovascular diseases, independently developed by RemeGen.
Ph2 data oral reported on ARVO2025
upfront payment of RMB 250 million, development and regulatory milestone payments of up to RMB 520 million, and sales milestone payments of up to RMB 525 million.
🇨🇳 #Remegen announced that its first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, #telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sjögren's syndrome (pSS) in China, as per the pre-specified study protocol. https://t.co/8BKLPPfJSX
The company will promptly submit a BLA to #CDE of 🇨🇳NMPA and plans to present the detailed data at major international academic conferences in due course.
Telitacicept was already approved for systemic lupus erythematosus (SLE) in China in March 2021, and for rheumatoid arthritis in this July.
In June, $VOR and 🇨🇳 #RemeGen announced entry into an exclusive license agreement granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize telitacicept. https://t.co/VAPtxG5ZMi
$VOR and 🇨🇳 #RemeGen announced entry into an exclusive license agreement granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize #telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA).
Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125 million consisting of an upfront payment of $45 million as well as $80 million of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4 billion, in addition to tiered royalties.
https://t.co/q09AG9lGJa
Telitacicept is a novel, investigational fusion protein that selectively inhibiting #BlyS (also known as #BAFF) and #APRIL - cytokines critical to B cell survival - telitacicept reduces autoreactive B cells and autoantibody production.
RemeGen is conducting a global Phase 3 clinical trial which is now enrolling in the United States, Europe, and South America, with initial results expected in the first half of 2027.
Telitacicept is approved in China for SLE, RA, and gMG. Annual sales volume to exceed 1.5 million units in 2024.
🟢ا $VOR
🔸ا Vor Biopharma
أعلنت عن توقيع اتفاقية ترخيص عالمية
مع #Remegen للدواء #telitacicept
السهم يتداول على ارتفاع 100%
عند 1.12$
🔸ا #الأسهم_الأمريكية
$VOR and 🇨🇳 #RemeGen announced entry into an exclusive license agreement granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize #telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA).
Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125 million consisting of an upfront payment of $45 million as well as $80 million of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4 billion, in addition to tiered royalties.
https://t.co/q09AG9lGJa
Telitacicept is a novel, investigational fusion protein that selectively inhibiting #BlyS (also known as #BAFF) and #APRIL - cytokines critical to B cell survival - telitacicept reduces autoreactive B cells and autoantibody production.
RemeGen is conducting a global Phase 3 clinical trial which is now enrolling in the United States, Europe, and South America, with initial results expected in the first half of 2027.
Telitacicept is approved in China for SLE, RA, and gMG. Annual sales volume to exceed 1.5 million units in 2024.
🇨🇳 #ASCO2025 oral presentation #Remegen's disitamab vedotin (DV) + Junshi's toripalimab (PD-1) + CAPOX or trastuzumab vs SOC in Ph2 1L HER+ la/m G/GEJ Cancer https://t.co/16e18bjYAo
HER2-overexpressing pts,
PD-1-trastuzumab-CAPOX vs. DV + PD-1 + chemo vs. DV + PD-1 + trastuzumab
ORR: 66.7% vs 82.4% vs 68.8%;
mPFS: NR vs NR vs 14.1 months
12-month PFS rate: 66.3%, 67% and 53.6%；
HER2-low-expressing
DV + PD-1 + CAPOX vs. PD-1 + CAPOX
ORR: 72.0% vs 47.8%;
mPFS: 9.9 vs 7.2 months
🇨🇳 #RemeGen’s #telitacicept (#RC18) was approved in #China for a new indication: generalized myasthenia gravis (gMG).
Previously, telitacicept had been approved in China for two indications—systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Telitacicept is a dual-target fusion protein antibody that simultaneously targets BLyS and APRIL.
🇨🇳 #RemeGen announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV), the first domestically approved #ADC in #China, in combination with the PD-1 inhibitor toripalimab versus the standard chemotherapy as 1L HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC) has reached its two primary endpoints of PFS and OS. https://t.co/yuRAzNpRDV
Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of #Remegen Disitamab Vedotin #ADC as a First-Line Therapy for HER2-Expressing (IHC-1+/2+/3+) Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS (RC48-C016) $PFE
sig diffs and clinically meaningful benefits on PFS & OS for Disitamab Vedotin+toripalimab vs chemo in 1L HER2-expressing LA/metastatic urothelial carcinoma
Remegen to file in China
https://t.co/ECppLaE4b9
#Remegen’s lupus drug surfaces with phase III #myastheniagravis data https://t.co/q6mw1jvfej #research #neurology #telitacicept #Chinabiotech
🇨🇳 #Remegen Announces Exciting Results of #Telitacicept (#RC18) Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis in #AAN2025 https://t.co/RCtiN9maHm
🇨🇳 #SABCS2024 #RemeGen presented the data from a phase III study (RC48-C006, NCT03500380) of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced breast cancer with liver metastasis (BCLM). https://t.co/lhdyjTJFVu
Construction began on several factory plants and projects in #Shanghai's #Zhangjiang Innovative Medicine Industry Base. Key projects include #Junshi Biosciences' innovative #medicine industry base and #RemeGen Biosciences' global R&D headquarter, with a combined #investment of 5.6 bln yuan.
Once completed, these projects will boost the local #pharmaceutical economy, accelerate regional #biomedical innovation and attract more industry pioneers to the base.
#InvestinShanghai
Sergeants Smith,Walker and Lewis from the Army Film & photographic Unit who jumped on the first day of Operation Market Garden - Sept 1944. This was taken shortly after being evacuated across the Rhine. #ww2 #worldwar2 #marketgarden #operationmarketgarden #remegen
Last Seen Hashtags on Sotwe
elarb6
covertbullying
Seen from Indonesia
trade
Seen from United States
incest
Seen from Poland
momson(((())))***+filter:native_video
Seen from Argentina
omegle
Seen from Chile
momson()*****************************************************
Seen from Australia
marcomartely
Seen from South Africa
แนวแม่ลูก
Seen from Thailand
suegro
Seen from Mexico
Most Popular Users
Elon Musk 
@elonmusk
241.1M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.4M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.1M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.3M followers
KATY PERRY
@katyperry
88.7M followers
Taylor Swift
@taylorswift13
82.6M followers
Lady Gaga
@ladygaga
74.1M followers
Virat Kohli
@imvkohli
71.5M followers
Kim Kardashian
@kimkardashian
70.3M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.5M followers
Neymar Jr
@neymarjr
64.4M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.8M followers
X
@x
60.8M followers